Campbell Alliance has named Nader Maeymo-Rad as CEO.
Neuymi-Rad joined the company shortly after its inception in 1997, and has played a key role in the growth of the firm since.
His appointment is part of Campbell Alliance's - a business segment of inVentiv Health - plans to shake up its leadership team.
Current CEO John Campbell will take his place at the helm of a new comittee of the Campbell Alliance board of directors, along side Ann Campbell, who steps down as president.
The board will focus on strategic growth opportunities in the US and abroad.
Of the company's new strategy, Ms. Campbell said: "Today, as an inVentiv Health company, we have access to tremendous resources on a global scale to make our accelerated growth plan a reality.
“With Nader in place we are well positioned to pursue an aggressive growth plan focused on external opportunities knowing that our core business is in good hands.”
Sucampo Pharmaceuticals has announced changes within its research and development (R&D) team.
The discovery, development and commercialization company appointed Gayle Doleck as its new part-time executive advisor, R&D.
His responsibilities will be shared by senior medical officer and VP of European operations at Sucampo AG (SAG), Peter Lichtlen.
Dolecek joined Sucampo from AAC Consulting Group in May 2006 as senior VP of R&D. He has since joined the board of directors.
Lichtlen – a more recent addition to the firm – joined SAG in July 2011, and currently oversees clinical development activities in the US, the European clinical and regulatory efforts.
Richard Head has been appointed as director at The Research Partnership as part of what the company says is its strategy for growth plans.
Previously a director at Cegedim Strategic Data, Head will take on the task of developing the European side of the business, and will work within the EU team.
Mark Jeffery, founding director of the British-based company said: “We are delighted that Richard has joined the company.
“As we continue to grow our European business, we need talented individuals like Richard who can support our existing business and continually look at ways to develop and deliver new services.”
Medivation has drafted in Cheryl Cohen as their new chief commercial officer.
Prior to joining the company, Cohen was president of pharmaceutical and biotech consultancy firm CLC Consulting, who worked with Medivation on several projects.
In her new role, she will head sales and marketing.
David Hung, president and CEO, said: "We have worked closely with Cheryl as a consultant since 2008, and thus have had the opportunity to observe her strong commercial leadership capabilities first hand.
“Cheryl's substantial experience and demonstrated track record in pharmaceutical sales, marketing and reimbursement will be tremendous assets to Medivation in our efforts to ensure a successful launch.”
Omega-3 fatty acids specialists Catabasis Pharmaceuticals has hired Joanne Donovan as its new chief medical officer.
Donovan take on the biopharma’s clinical development and clinical regulatory strategy in the build up to the company’s human clinical trials of its lead program in type 2 diabetes.
“Joanne’s extensive clinical and business development experience will be invaluable to Catabasis as we plan to initiate a Phase 1 clinical study for our diabetes program later this fall,” said Jill C. Milne, chief executive officer and co-founder of Catabasis.
“Having led multiple clinical programs through all phases of development from discovery to approvals, Joanne brings strong leadership capabilities and a unique skill set to Catabasis. We look forward to working closely with her as we evolve from a discovery to a clinical stage company.”